Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus
- PMID: 3640590
- PMCID: PMC180564
- DOI: 10.1128/AAC.30.3.382
Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus
Abstract
The efficacy of ciprofloxacin for experimental aortic valve endocarditis in rabbits infected by either a methicillin-susceptible or a methicillin-resistant strain of Staphylococcus aureus was compared with standard therapy of nafcillin or vancomycin, respectively. After 4 days of therapy, ciprofloxacin reduced the counts of organisms in aortic valve vegetations as effectively as the standard regimen for both susceptible and resistant strains. Mean concentrations of ciprofloxacin in serum achieved 1 h after a dose exceeded the MBC for each strain by twofold or less. In these experiments ciprofloxacin was as efficacious as standard regimens currently used to treat staphylococcal infections in humans.
Similar articles
-
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 1988 May;32(5):747-51. doi: 10.1128/AAC.32.5.747. Antimicrob Agents Chemother. 1988. PMID: 3164989 Free PMC article.
-
Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 1987 Apr;31(4):527-30. doi: 10.1128/AAC.31.4.527. Antimicrob Agents Chemother. 1987. PMID: 3649202 Free PMC article.
-
Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.Antimicrob Agents Chemother. 1984 Jul;26(1):61-4. doi: 10.1128/AAC.26.1.61. Antimicrob Agents Chemother. 1984. PMID: 6236747 Free PMC article.
-
Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.Am J Med. 1985 Jun 28;78(6B):116-27. doi: 10.1016/0002-9343(85)90374-2. Am J Med. 1985. PMID: 3893113 Review.
-
Medical treatment of staphylococcal infective endocarditis.Eur Heart J. 1995 Apr;16 Suppl B:80-3. doi: 10.1093/eurheartj/16.suppl_b.80. Eur Heart J. 1995. PMID: 7671931 Review.
Cited by
-
Methicillin-resistant staphylococci: detection methods and treatment of infections.Antimicrob Agents Chemother. 1989 Jul;33(7):995-9. doi: 10.1128/AAC.33.7.995. Antimicrob Agents Chemother. 1989. PMID: 2675760 Free PMC article. Review. No abstract available.
-
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003. Drugs. 1988. PMID: 3292209 Review.
-
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 1989 Aug;33(8):1184-7. doi: 10.1128/AAC.33.8.1184. Antimicrob Agents Chemother. 1989. PMID: 2802547 Free PMC article.
-
Methicillin-resistant staphylococci.Clin Microbiol Rev. 1988 Apr;1(2):173-86. doi: 10.1128/CMR.1.2.173. Clin Microbiol Rev. 1988. PMID: 3069195 Free PMC article. Review.
-
Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 1988 May;32(5):747-51. doi: 10.1128/AAC.32.5.747. Antimicrob Agents Chemother. 1988. PMID: 3164989 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases